- Home
- RMAX vs IMUX Comparison
RMAX vs IMUX Comparison
Compare RMAX & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RMAX | IMUX |
|---|---|---|
| Founded | 1973 | 2016 |
| Country | United States | United States |
| Employees | N/A | 66 |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 193.4M | 200.4M |
| IPO Year | 2013 | 2013 |
Fundamental Metrics
Financial Performance| Metric | RMAX | IMUX |
|---|---|---|
| Price | $10.07 | $15.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $11.40 | ★ $36.00 |
| AVG Volume (30 Days) | ★ 272.1K | 205.3K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | ★ 0.60 | N/A |
| Revenue | ★ $195,929,000.00 | N/A |
| Revenue This Year | $2.62 | N/A |
| Revenue Next Year | $1.24 | N/A |
| P/E Ratio | $16.43 | ★ N/A |
| Revenue Growth | ★ 11.13 | N/A |
| 52 Week Low | $5.46 | $0.51 |
| 52 Week High | $11.62 | $15.84 |
Technical Indicators
Market Signals| Indicator | RMAX | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 60.94 | 67.06 |
| Support Level | $8.77 | $0.74 |
| Resistance Level | $11.51 | $15.77 |
| Average True Range (ATR) | 0.37 | 1.11 |
| MACD | 0.04 | -0.04 |
| Stochastic Oscillator | 91.04 | 88.46 |
Price Performance
Historical ComparisonAbout RMAX RE/MAX Holdings Inc.
RE/MAX Holdings Inc operates as a franchisor of real estate brokerage services. It recruits and retains agents and sells franchises. The company's operating segments include Real Estate, Mortgage, Marketing Funds, and Others. It generates maximum revenue from the Real Estate segment.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.